IFEX DIN 02241357
Health Canada record
| Active ingredient(s) | IFOSFAMIDE 1 G |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01AA06 IFOSFAMIDE |
| Original market date | 20-Mar-2001 |
| Current status date | 09-Sep-2003 |
| Source | Health Canada DPD |
Establishment licence of the holder
Baxter Corporation — licence 100278, currently licensed, last inspection rating C (2026-08-11).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing IFOSFAMIDE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02241356 | IFEX | BAXTER CORPORATION | Powder For Solution | IFOSFAMIDE 3 G | Marketed |
| 00797227 | IFEX PWS 1GM/VIAL | BRISTOL LABS DIVISION OF BRISTOL-MYERS SQUIBB | Powder For Solution | IFOSFAMIDE 1 G | Cancelled Post Market |
| 00797235 | IFEX PWS 2G/VIAL | BRISTOL LABS DIVISION OF BRISTOL-MYERS SQUIBB | Powder For Solution | IFOSFAMIDE 2 G | Cancelled Post Market |
| 00808601 | IFEX PWS 3GM/VIAL | BRISTOL LABS DIVISION OF BRISTOL-MYERS SQUIBB | Powder For Solution | IFOSFAMIDE 3 G | Cancelled Post Market |
| 02246565 | IFOSFAMIDE FOR INJECTION | FRESENIUS KABI CANADA LTD | Powder For Solution | IFOSFAMIDE 1 G | Cancelled Post Market |
| 02246566 | IFOSFAMIDE FOR INJECTION | FRESENIUS KABI CANADA LTD | Powder For Solution | IFOSFAMIDE 3 G | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 623 | 2002-02-04 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
| 1848 | 1999-12-09 | New Drug Submission (NDS) |
International API supply for IFOSFAMIDE
1 valid EDQM Certificates of Suitability from 1 holders. 5 active FDA Drug Master Files.
Request a quote for IFEX